Lung cancer: From early detection to precision oncology: Are we entering a new era of personalised cancer care?

Toi Blogs Introduction: Changing the story of lung cancer Lung cancer remains one of the leading causes of cancer-related deaths worldwide. For decades, a diagnosis of lung cancer was associated with limited treatment options and poor outcomes, particularly when the disease was detected at an advanced stage. However, lung cancer management is undergoing a remarkable transformation. Advances in early detection, molecular diagnostics, targeted therapies, immunotherapy and artificial intelligence are changing how we diagnose and treat this disease. Today, the question is no longer simply where did the cancer originate? We increasingly ask: What biological changes are driving the cancer, and which treatment is most likely to work against them? This is the foundation of precision oncology. 1. Understanding lung cancer: Not all lung cancers are the same Lung cancer is broadly classified into two major categories: · Non-Small Cell Lung Cancer (NSCLC): Accounts for approximately 85% of cases. It includes adenocarcinoma, squamous cell carcinoma and large-cell carcinoma. · Small Cell Lung Cancer (SCLC): A more aggressive form, characterised by rapid growth and an early tendency to spread. Adenocarcinoma is the most common subtype of NSCLC and is frequently encountered even among people who have never smoked. Although smoking remains the most important preventable risk factor, lung cancer can also occur due to second-hand smoke, air pollution, occupational exposure, radon and genetic susceptibility. Importantly, lung cancer should never be considered exclusively a smoker's disease. 2. Lung cancer screening: Can we detect cancer before symptoms appear? One of the most effective ways to improve cancer outcomes is to detect the disease before it produces symptoms. Early-stage lung cancer may not cause persistent cough, chest pain, breathlessness or coughing up blood. By the time symptoms develop, the disease may already be locally advanced or metastatic. Low-Dose Computed Tomography (LDCT) is currently the established imaging method for lung cancer screening in appropriately selected high-risk individuals. Unlike a conventional CT scan, LDCT uses a substantially lower radiation dose and can identify small lung nodules that may not be visible on a chest X-ray. Evidence from major screening studies has demonstrated that LDCT screening can reduce lung cancer mortality in appropriately selected high-risk populations. For example, the commonly used US Preventive Services Task Force criteria recommend annual LDCT screening for individuals who: ·Are between 50 and 80 years of age. ·Have a smoking history of at least 20 pack-years. ·Currently smoke or quit within the preceding 15 years. A pack-year is calculated by multiplying the number of cigarette packs smoked daily by the number of years of smoking. Does everyone need a lung cancer screening CT? No. Screening is not the same as diagnostic testing. Routine annual CT scans are not recommended for every healthy individual or every nonsmoker. The benefits, false-positive findings, unnecessary investigations and radiation exposure must be considered. In India, where smoking patterns, biomass fuel exposure, air pollution and lung cancer demographics differ from Western populations, screening strategies need to be adapted to local evidence and risk profiles. For individuals with persistent respiratory symptoms, unexplained weight loss, haemoptysis or suspicious imaging findings, appropriate diagnostic evaluation is necessary irrespective of screening eligibility. 3. Precision oncology: Treating the mutation, not just the tumour Perhaps the most significant development in lung cancer treatment has been the understanding that cancers with identical appearances under a microscope may have completely different molecular characteristics. Cancer develops through genetic and molecular alterations that allow cells to grow uncontrollably, evade immune surveillance and spread to other organs. Some of these alterations act as molecular switches, driving tumour growth. These are called oncogenic driver alterations. Modern molecular testing can identify these alterations and help select therapies directed against specific cancer-driving pathways. Important molecular biomarkers in NSCLC include: · EGFR: Mutations can be treated with targeted medicines such as osimertinib. · ALK: Rearrangements can respond to ALK inhibitors such as alectinib and lorlatinib. · ROS1: Rearrangements have specific targeted treatment options. · KRAS G12C: Targeted inhibitors are available for selected patients. · BRAF V600E: Can be treated with combined BRAF and MEK inhibition. · MET exon 14 skipping: May respond to MET inhibitors. · RET: RET fusion-positive cancers can respond to selective RET inhibitors. · NTRK: Rare gene fusions may be treated with tumour-agnostic targeted therapies. · HER2 (ERBB2): Specific mutations have emerging and established targeted treatment options. This is why comprehensive molecular profiling is increasingly becoming an essential component of advanced NSCLC management. 4. What is next-generation sequencing (NGS)? Traditionally, cancer testing involved examining one or two genes at a time. However, lung cancer can harbour several different molecular alterations, and sequential testing may consume valuable tissue and delay treatment decisions. Next-Generation Sequencing (NGS) allows multiple cancer-associated genes to be analysed simultaneously. A comprehensive molecular work-up may include: ·EGFR, ALK, ROS1, BRAF and KRAS. ·MET, RET, NTRK and HER2. ·Additional emerging biomarkers such as NRG1. ·PD-L1 testing to assess potential suitability for immunotherapy. Testing may involve tumour tissue obtained through biopsy or surgery. When adequate tissue is unavailable, or a faster assessment is needed, circulating tumour DNA (ctDNA) testing through a blood sample, commonly called liquid biopsy, can provide additional information. However, a negative liquid biopsy does not necessarily exclude a mutation. Some tumours release very little circulating DNA into the bloodstream. Therefore, tissue testing should still be considered when clinically feasible. The goal is to identify the molecular characteristics of the cancer before selecting the most appropriate systemic treatment. 5. Immunotherapy: Helping the immune system fight cancer Another major advancement has been immunotherapy. Cancer cells can develop mechanisms to escape recognition and destruction by the immune system. One such mechanism involves the PD-1/PD-L1 pathway. Immune checkpoint inhibitors, including pembrolizumab, nivolumab and atezolizumab, can help restore the immune system's ability to recognise and attack cancer cells. PD-L1 expression is an important biomarker in treatment selection, although it is not the only factor. An important clinical principle is that immunotherapy should not automatically be preferred simply because PD-L1 expression is high. Patients with certain oncogenic driver alterations, particularly EGFR mutations and ALK rearrangements, may derive less benefit from immunotherapy when compared with appropriate targeted treatment strategies. Therefore, molecular testing and PD-L1 assessment should be interpreted together, rather than in isolation. 6. Does precision oncology mean the end of chemotherapy? Absolutely not. Precision oncology does not replace conventional oncology. Instead, it integrates molecularly targeted treatments, immunotherapy, chemotherapy, radiation therapy and surgery into a scientifically informed treatment strategy. Depending on the stage and molecular profile, patients may receive: ·Surgery for appropriately selected early-stage disease. ·Stereotactic body radiotherapy (SBRT) for selected early-stage patients who are medically unsuitable for surgery. ·Chemotherapy and radiation for locally advanced disease. ·Targeted therapy for cancers with actionable molecular alterations. ·Immunotherapy alone or in combination with chemotherapy in appropriately selected patients. ·Combination or sequential treatment approaches when resistance develops. The treatment decision must consider tumour biology, disease stage, performance status, comorbidities, patient preferences and treatment accessibility. 7. The future: Liquid biopsy, artificial intelligence and personalised cancer care The future of lung cancer management will increasingly depend on integrating multiple sources of biological information. Liquid biopsy can help detect molecular alterations, identify resistance mechanisms and monitor changes in tumour DNA during treatment. For example, a patient initially responding to targeted therapy may develop a new resistance alteration. Repeat molecular profiling can sometimes identify the mechanism responsible and help guide the next treatment decision. Artificial intelligence is also transforming radiology, pathology and molecular diagnostics. AI-assisted imaging may help identify suspicious lung nodules, while computational pathology and genomic analysis may provide additional insights into tumour behaviour. These technologies are promising, but they must complement—not replace—clinical judgement and validated diagnostic methods. Conclusion: Early detection plus precision treatment can change outcomes Lung cancer care is moving beyond a one-size-fits-all approach. Screening offers an opportunity to detect selected high-risk individuals before symptoms develop. Molecular profiling helps identify the biological drivers of cancer. Targeted therapies and immunotherapy provide treatment options that were unimaginable a few decades ago. The most important message is that every lung cancer patient deserves an appropriate diagnostic evaluation, accurate staging and consideration of molecular testing when indicated. The future of lung cancer treatment is not simply about treating cancer earlier. It is about understanding each cancer better and choosing the right treatment for the right patient at the right time. Disclaimer This article is intended for general educational purposes and does not replace professional medical consultation, diagnosis or treatment. Lung cancer screening is appropriate only for selected individuals based on established risk factors and clinical assessment. Molecular testing and treatment decisions should be individualised and guided by a qualified oncology team. Disclaimer : Views expressed above are the author's own.